Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2021 | Future directions in MPN therapy

Laura Michaelis • 13 Aug 2021
Texas MPN Workshop 2021
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Interferon Navitoclax Ropeginterferon alfa-2b Venetoclax

Laura Michaelis, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the future of myeloproliferative neoplasm (MPN) therapy and the implications for patients with MPNs. Dr Michaelis explains that more data is expected to be seen from trials investigating novel agents such as IDH-1/2 inhibitors and BCL-2 inhibitors, agents which have already received approval for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia. Dr Michaelis further talks on the prospects of immunotherapy for myelofibrosis and other advanced MPNs. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.

More from Laura Michaelis

Mitigating COVID-19 infection risk for MPN patients
Laura Michaelis • 10 Nov 2022
3:22
State-of-the-art developments in MPNs
Laura Michaelis • 13 Aug 2021
1:57
The latest updates on COVID-19 and MPNs
Laura Michaelis • 13 Aug 2021

Related Videos

0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:59
The common clinical manifestations of BPDCN
Anthony Stein • 15 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals